CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 18 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-26 | Green John L. Chief Financial Officer | Sale | −17,813 | $8.86 | $158K | 3,841 |
| 2021-04-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +2,121 | $5.66 | $12K | 2,121 |
| 2021-04-01 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +2,068 | $5.66 | $12K | 2,068 |
| 2021-03-11 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2021-03-11 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2021-03-11 | Shegog Todd Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2021-03-11 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2021-03-11 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2021-03-11 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2021-02-25 | Green John L. Chief Financial Officer | Grant or award | +524 | 21,654 | ||
| 2021-02-22 | Shegog Todd Director | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2021-02-10 | Robbins Andrew R President and CEO | Grant or award · Stock Option (Right to Buy) | +315,200 | 315,200 | ||
| 2021-02-10 | Green John L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +111,300 | 111,300 | ||
| 2021-02-10 | Green John L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +270,746 | 270,746 | ||
| 2021-02-10 | Sachs Jessica Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +126,500 | 126,500 | ||
| 2021-02-01 | Sachs Jessica Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2021-01-04 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +1,641 | 1,641 | ||
| 2021-01-04 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +1,575 | 1,575 | ||
| 2020-12-07 | Robbins Andrew R President and CEO | Grant or award · Stock Option (Right to Buy) | +456,693 | 456,693 | ||
| 2020-12-01 | Green John L. Chief Financial Officer | Grant or award | +1,748 | 1,748 |
Page 8 of 14 · 268 trades